Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

Sanofi has entered exclusive negotiations to sell a 50% controlling stake in its consumer health business ... Opella, which houses brands including Allegra, generated sales of $5.7 billion ...

Sanofi Consumer Health Care India Ltd, the pharmaceutical company that makes Combiflam among other consumer drugs, announced to sell 26% of its equity shares to Opal Bidco SAS along with U.S ...

The drugmaker this week raised its annual profit forecast when announcing exclusive negotiations with US buyout firm Clayton Dubilier & Rice for the sale of its consumer health unit. Chief executive ...

I WAS SPECIFICALLY LOOKING FOR BRANDS THAT WERE KNOWN TO BE DURABLE, HAVE GREAT SAFETY QUALIFICATIONS, AND SOMETHING THAT WAS FUEL EFFICIENT. CONSUMER REPORTS JUST RELEASED ITS FIRST EVER BRAND ...